Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.52 USD | +0.87% | +2.80% | -13.63% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.63% | 1.19B | |
+41.88% | 54.04B | |
+43.57% | 41.96B | |
-1.16% | 41.92B | |
-7.59% | 28.35B | |
+12.16% | 26.35B | |
-22.43% | 19B | |
+7.81% | 13B | |
+28.70% | 12.28B | |
+25.41% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $79 From $82, Maintains Strong Buy Rating